INTRODUCTION {#s05}
============

Neuroblastoma (NB) is the most common extra cranial solid tumor in children younger than age 14 years, representing 7% of all childhood cancer diagnoses in the United States (US) between 1999 and 2013,^[@B1]^ 7.6% of childhood cancer diagnoses in Europe from 1998 to 2007,^[@B2]^ and 8% of childhood cancer diagnoses in Egypt between 2002 and 2010.^[@B3]^ High-risk NB (HRNB) represents nearly half of all newly diagnosed patients with NB.^[@B4]^ HRNB requires intensive multimodality treatment, and gradual improvements in overall survival have been achieved through the adoption of more intensive therapy and novel immunotherapeutic strategies.^[@B5]^ Several randomized clinical trials demonstrated that high-dose chemotherapy (HDC) with stem-cell rescue (SCR) improved event-free survival (EFS) of patients with HRNB relative to observation,^[@B6]^ low-dose chemotherapy,^[@B7]^ or dose-intensive chemotherapy.^[@B8]^ There is no international consensus on the best HDC regimen for consolidation treatment of HRNB. Total-body irradiation has been removed from HDC-SCR on the basis of data from the Children's Oncology Group COG A3973 study, which demonstrated similar 5-year EFS after HDC-SCR with carboplatin, etoposide, and melphalan (CEM), followed by delayed primary site--involved field radiotherapy compared with EFS after the CCG 3891 regimen of total-body irradiation and lower-dose CEM.^[@B9]^ A retrospective analysis by the European Group for Blood and Marrow Transplantation of 2,741 patients with HRNB who received HDC-SCR in Europe from 1984 to 2006 demonstrated that busulfan and melphalan (Bu/Mel) therapy resulted in a significantly improved 5-year overall survival rate of 48% in first remission compared with other reported regimens.^[@B10]^ Hartman et al^[@B11]^ retrospectively reviewed 218 patients who underwent transplantation at Gustave Rousey Institute from 1980 through 1996 and demonstrated similarly that Bu/Mel was associated with better progression-free survival than other regimens. These data prompted a randomized controlled trial that was conducted by the NB group of the International Society of Pediatric Oncology (the HRNBL1/SIOPEN trial) that demonstrated superior survival for children with responsive HRNB who received Bu/Mel compared with CEM (3-year EFS: 49% *v* 33%; *P* \< .001) and with less acute toxicity.^[@B12]^ As a result, Bu/Mel is the preferred consolidation chemotherapy regimen in Europe and some areas in the Middle East. Although Bu/Mel has been studied in pilot trials performed in North America, it has not been adopted as the standard North American consolidation regimen as a result of the discrepancy in outcomes for CEM noted in the HRNBL1/SIOPEN trial compared with those in the COG A3973 trial^[@B9]^ and the results of the recently completed randomized trial ANBL0532 that demonstrated a superior outcome after tandem transplantation consolidation compared with single transplantation.^[@B13]^

The purpose of our study was to compare acute complications, regimen-related toxicities, and 100-day survival between two regimens of HDC-SCR for the treatment of HRNB administered in two different centers within two countries with different economic status and different pretransplantation health problems.

PATIENTS AND METHODS {#s06}
====================

We conducted a retrospective cohort study that compared patients with HRNB who were treated at either Fred Hutchinson Cancer Research Center (FH) in Seattle, WA, between 2005 and 2015 or El-Sheikh Zayed Specialized Hospital (SZ) in 6th of October, Egypt, between 2009 and 2015. SZ is the second largest hematopoietic cell transplantation (HCT) center in Egypt and performs the largest number of autologous transplantations in the country, with approximately 100 patients per year, of which 30 are pediatric patients who undergo autologous transplantation. FH is one of the largest bone marrow transplantation centers in the United States, with approximately 75 pediatric patients who undergo transplantation per year, approximately 10 of whom undergo autologous transplantation annually. Research was conducted after approval was obtained from the institutional review boards of both institutions. Eligible patients had HRNB classified by using the Children's Oncology Group risk classification incorporating the international staging system,^[@B14]^ age, MYCN status, ploidy, and histology at diagnosis. Patients were included if they underwent a single HDC-SCR with Bu/Mel at SZ or with CEM at FH regardless of where they received induction therapy. Data for eligible individuals were collected from medical records and transplantation databases at each institution from the time of transplant admission until 100 days after stem-cell infusion (D+100). The following data were collected: demographics, disease status at the time of transplantation, pretransplant morbidity, HCT comorbidity index (HCT-CI),^[@B15]^ post-transplantation acute complications according to the Common Toxicity Criteria of Adverse Events (version 4.03),^[@B16]^ and D+100 mortality.

HD Chemotherapy {#s07}
---------------

At SZ, all patients received myeloablative conditioning with oral busulfan 5 mg/kg/d, divided into four oral doses---or 4 mg/kg/d if younger than age 10 years---on each of days −7, −6, −5, and −4, and intravenous melphalan 70 mg/m^2^/d on days −3 and −2. Therapeutic drug monitoring was not available, and busulfan levels were therefore not obtained. Anticonvulsant prophylaxis with phenytoin 6 mg/kg/d was administered on days −7 through −2. At FH, all patients received myeloablative conditioning with carboplatin 425 mg/m^2^ per dose---14.2 mg/kg for patients \< 12 kg---on days −7, −6, −5, and −4 (dose modified according to pretransplant glomerular filtration rate and the Calvert formula)^[@B9]^; etoposide 338 mg/m^2^ per dose---11.3 mg/kg for patients \< 12 kg---on days −7, −6, −5, and −4; and melphalan 70 mg/m^2^ per dose---2.3 mg/kg for patients \< 12 kg---on days −7, −6, and −5.

Supportive Care {#s08}
---------------

Eligible patients at both institutions received granulocyte colony-stimulating factor (G-CSF)--mobilized peripheral blood stem cells with an infused cell dose of ≥ 2 × 10^6^ CD34-positive cells per kilogram. At SZ, G-CSF 5 μg/kg/d was administered from day +6 post-transplantation until neutrophils \> 1,000/mm^3^ for 3 consecutive days. At FH, G-CSF 5 μg/kg/d was administered starting 24 hours after transplantation until neutrophils \> 2,000/mm^3^ for 3 consecutive days. At both centers, patients received transfusions with packed RBCs for hematocrit \< 20% and platelet transfusion for a platelet count \< 10,000/μL or in the presence of bleeding. Prophylactic ursodeoxycholic acid was used in both cohorts. Policies for the use of prophylactic antibiotics, antivirals, and antifungal were the same.

Evaluation of Acute Toxicities {#s09}
------------------------------

Toxicities were graded according to the Common Toxicity Criteria of Adverse Events (version 4.03).^[@B16]^ Sinusoidal obstruction syndrome (SOS) was defined according to modified Seattle^[@B17]^ or Baltimore criteria.^[@B18]^ Time to engraftment was defined as the first of 3 consecutive days of absolute neutrophil count \> 500/μL and the first of 3 consecutive days of platelets ≥ 20,000/μL, at least 7 days from the last platelet transfusion. Transfusion support was quantified as the number of packed RBC and platelet transfusions received. Blood stream infection was defined as the isolation of bacteria not normally known to colonize the skin from at least one blood culture. Blood stream infections for bacteria that typically colonize the skin---coagulase-negative *Staphylococcus*, *Propionibacterium*, and *Streptococcus* viridians group---were defined as two consecutive positive blood cultures within 72 h, or one positive peripheral blood culture and one positive culture from an indwelling catheter within 72 h. All blood cultures were obtained in response to an infectious indication, usually fever.

Statistical Analysis {#s10}
--------------------

Quantitative data were expressed as medians, means, minimum, and maximum, and were compared by using Mann-Whitney *U* test. Qualitative data were expressed as numbers and percentages, and were compared by using χ^2^ test or Fischer's exact test when appropriate. A significance level of .05 was used in all statistical tests.

RESULTS {#s11}
=======

Patient Characteristics {#s12}
-----------------------

Among the 50 and 95 patients at FH and SZ, respectively, who were identified as having received HDC-SCR for upfront HRNB therapy during the study period, 44 individuals at FH received CEM and 77 patients at SZ received Bu/Mel and were eligible for review. Patients were excluded if they were conditioned with regimens other than CEM (n = 5), Bu/Mel (n = 0), and tandem transplantation (n = 1), or if records were unavailable (n = 12). Age at transplantation was significantly higher in the SZ-Bu/Mel group compared with the FH-CEM group (*P* = .002). Characteristics of patients at each center are listed in [Table 1](#T1){ref-type="table"}.

###### 

Patient Characteristics
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Pretransplant Comorbidity {#s13}
-------------------------

HCT-CI scores were obtained for all patients and categorized into three groups: the first group with an HCT-CI score of 0, the second group with an HCT-CI score of 1 to 2, and the third group with and HCT-CI score of ≥ 3 ([Table 1](#T1){ref-type="table"}). There was no statistically significant difference in the distribution of HCT-CI scores between centers. We additionally categorized patients into HCT-CI scores 0 and ≥ 1 and observed no statistically significant difference in the proportion of patients with score ≥ 1 between the FH-CEM cohort (31.8%) and the SZ-Bu/Mel cohort (37.7%). Pretransplant hepatic comorbidity was significantly higher in the SZ-Bu/Mel cohort than in the FH-CEM cohort (88% *v* 47.4%, respectively; *P* = .05). In addition, pretransplant hepatitis was present only in the SZ-Bu/Mel cohort.

Acute Complications of HDC-SCR {#s14}
------------------------------

Median length for hospital stay in the FH-CEM cohort was 32 days, which was not significantly different compared with 36 days in the SZ-Bu/Mel cohort (*P* = .07). Details of acute complications are listed in [Table 2](#T2){ref-type="table"}.

###### 

Acute Complications of High-Dose Chemotherapy With Stem-Cell Rescue
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Hematologic Toxicities {#s15}
----------------------

Median number of infused CD34-positive stem cells was significantly higher in the FH-CEM cohort compared with the SZ-Bu/Mel cohort (*P* ≤ .001). Median time for neutrophil engraftment was 12 days (range, nine to 48 days) for the SZ-Bu/Mel cohort and longer than the 10 days (range, eight to 39 days) observed for the FH-CEM cohort (*P* \< .001; [Fig 1](#f1){ref-type="fig"}). Median time to platelet engraftment was 20 days (range, 12 to 78 days) in the SZ-Bu/Mel cohort compared with 18 days (range, 10 to 50 days) in the FH-CEM cohort (*P* \< .001). We used 3.9 CD34/kg as a cutoff value to compare the median time to neutrophil and platelet engraftments in both cohorts. We found that median times for neutrophil and platelet engraftments were significantly lower in patients who received an infused stem-cell dose of ≥ 3.9 × 10^6^/kg compared with those who received a stem-cell dose of \< 3.9 × 10^6^/kg in FH-CEM and SZ-Bu/Mel cohorts, respectively (FH-CEM: *P* = .05 and .033, respectively; SZ-Bu/Mel: *P* = .03 and .045, respectively). Median number of RBC transfusions in the FH-CEM cohort was three (range, zero to 10 transfusions) compared with two (range, zero to 16 transfusions) in the SZ-Bu/Mel cohort (*P* = .033). Median number of platelet transfusions was also significantly higher in the FH-CEM cohort compared with the SZ-Bu/Mel cohort at six transfusions (range, one to 22 transfusions) versus one transfusion (range, zero to 17 transfusions), respectively (*P* ≤ .001).

![Time to neutrophil and platelet engraftment. FH-CEM, carboplatin, etoposide, and melphalan at Fred Hutchinson Cancer Research Center; SZ-Bu/Mel, busulfan and melphalan at El-Sheikh Zayed Specialized Hospital.](JGO.17.00118f1){#f1}

Hepatic Toxicity {#s16}
----------------

There were no statistically significant differences in hepatic dysfunction---elevated liver enzymes---and hyperbilirubinemia between both cohorts ([Table 2](#T2){ref-type="table"}). Three patients (6.8%) were diagnosed with SOS in the FH-CEM cohort, whereas eight patients (10.4%) were diagnosed with SOS in the SZ-Bu/Mel cohort. Median time to the onset to SOS was 19 days after SZ-Bu/Mel conditioning compared with 7 days after FH-CEM conditioning (*P* = .033; [Fig 2](#f2){ref-type="fig"}). Details of the diagnostic criteria for SOS, underlying hepatitis infection, complications, and outcome are listed in [Table 3](#T3){ref-type="table"}. Using χ^2^ test, hepatitis infection was significantly related to the development of SOS (*P* \< .001). All SOS cases from the FH-CEM cohort were of moderate severity, whereas in the SZ-Bu/Mel cohort, four cases (50%) were severe and four cases (50%) were moderately severe. Underlying liver infection was present in all four of the severe cases and in one-half of the cases of moderate severity in the SZ-Bu/Mel cohort

![Time to onset of sinusoidal obstruction syndrome (SOS). FH-CEM, carboplatin, etoposide, and melphalan at Fred Hutchinson Cancer Research Center; SZ-Bu/Mel, busulfan and melphalan at El-Sheikh Zayed Specialized Hospital.](JGO.17.00118f2){#f2}

###### 

Characteristics of Patients With Sinusoidal Obstruction Syndrome
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Nephrotoxicity {#s17}
--------------

There were more patients with nephrotoxicity in the FH-CEM cohort than in the SZ-Bu/MEL cohort (*P* = .047), although two patients in the SZ-Bu/Mel group required dialysis as a result of hepatorenal syndrome as a complication of severe SOS.

Infectious Complications {#s18}
------------------------

Febrile neutropenia occurred commonly and was observed in 39 patients (88.6%) from the FH-CEM cohort and in 71 patients (92.2%) from the SZ-Bu/Mel cohort. The number of days with fever and days receiving antibiotics were significantly higher for the FH-CEM cohort compared with the SZ-Bu/Mel cohort ([Table 2](#T2){ref-type="table"}).

100-Day Transplant-Related mortality {#s19}
------------------------------------

Four patients who underwent transplantation after SZ-Bu/Mel died before day 100 ([Fig 3](#f3){ref-type="fig"}). All had severe SOS, developed respiratory failure, and required mechanical ventilation. Two patients developed hepatorenal syndrome and required dialysis. There was no transplantation-related mortality in the FH-CEM cohort.

![Kaplan-Meier curve of overall survival at 100 days between carboplatin, etoposide, and melphalan at Fred Hutchinson Cancer Research Center (FH-CEM) and busulfan and melphalan at El-Sheikh Zayed Specialized Hospital (SZ-Bu/Mel).](JGO.17.00118f3){#f3}

DISCUSSION {#s20}
==========

HDC-SCR plays a major role in the treatment strategy for HRNB, although there currently is no consensus about what comprises the best conditioning regimen. We explored the acute complications, regimen-related toxicities, and 100-day survival in two cohorts of patients with HRNB who were conditioned with either CEM or Bu/Mel. One cohort received HDC-SCR at a bone marrow transplantation (BMT) center located in Egypt, a developing lower middle-income country where the BMT program started in 1989,^[@B19]^ whereas the other cohort received HDC-SCR in the United States, a high-income country where the BMT program started in the early 1950s, with significantly larger numbers of transplantations having been performed.^[@B20]^ Egyptian patients with HRNB have been receiving the same Bu/Mel conditioning regimen used in Europe. Meanwhile, patients with HRNB in the United States, for the most part, have received CEM.

The prevailing public health problems in Egypt and the United States are different. Hepatitis is a major public health problem in Egypt, with intermediate endemicity for hepatitis B (2% to 5% hepatitis B surface antigen prevalence) and high endemicity for hepatitis C (17.5%).^[@B21]-[@B23]^ In this analysis, there were no significant differences in HCT-CI scores between FH-CEM and SZ-Bu/Mel cohorts; however, pretransplant hepatic comorbidities were significantly higher in the SZ-Bu/Mel cohort compared with the FH-CEM cohort. Of importance, there was a high incidence of hepatitis B and C infections in the SZ-Bu/Mel cohort---5.2% of patients were coinfected with both hepatitis B and C virus.

SOS developed in fewer patients in the FH-CEM cohort than in the SZ-Bu/Mel cohort. Ladenstein et al^[@B12]^ reported similar findings in the HRNBL1/SIOPEN trial. As Bu depletes intracellular glutathione and alters melphalan metabolism, glutathione-depleted cells are predisposed to the hepatotoxic metabolites of high-dose Mel^[@B24],[@B25]^ SOS developed earlier in the FH-CEM cohort compared with the SZ-Bu/Mel. Different studies that compared Bu/Mel and CEM reported similar results.^[@B12],[@B26]-[@B28]^ Although the frequency of SOS was higher in other studies by Proust-Houdemont et al^[@B29]^ and the HRNBL1/SIOPEN trial^[@B12]^ compared with SZ-Bu/Mel, severe SOS developed more frequently in the SZ-Bu/Mel group. The higher frequency of infectious hepatitis in the SZ-Bu/Mel group might be a contributing factor in the development of severe SOS. Several studies have demonstrated that pretransplant hepatitis infection increased the severity of SOS in recipients of stem-cell transplantation.^[@B30]-[@B32]^ Potential differences in the method of Bu administration between different centers might also be relevant to the frequency of occurrence of severe SOS. In the SZ-Bu/Mel cohort, oral Bu was used without therapeutic drug monitoring, whereas oral Bu with therapeutic drug monitoring was used until 2006 in Proust-Houdemont et al and until 2007 in the HRNBL1/SIOPEN trial, when intravenous Bu was used. Oral bioavailability of Bu is unpredictable, with marked interpatient variability in the plasma concentration, especially in children.^[@B33]^ Veal et al^[@B34]^ compared the pharmacokinetics of oral and intravenous Bu in patients with HRNB who were treated in the HRNBL1/SIOPEN trial. They reported that oral Bu was significantly related to the development of grade 3 and 4 hepatic toxicity and SOS. This is likely a result of the effect of the first-pass metabolism that leads to higher Bu concentrations in liver-enhancing hepatic toxicity.

The practice and supportive care of HDC-SCR differ between Egypt and the United States, which may be responsible, in part, for the difference in the pattern of acute toxicity of HDC-SCR between the two centers. The earlier use of G-CSF in the FH-CEM cohort---starting 24 hours after infusion compared with 6 days after stem-cell infusion in the SZ-Bu/Mel cohort---might explain, in part, the longer median time for neutrophil engraftment in SZ-Bu/Mel patients compared with FH-CEM patients. Longer median time can also be explained by differences in the infused cell dose. Median infused cell dose in the FH-CEM cohort was significantly higher than that in the SZ-Bu/Mel cohort (*P* \< .001). We found that the median times for neutrophil and platelet engraftments were significantly lower in patients who received an infused stem-cell dose of ≥ 3.9 × 10^6^ cells/kg compared with those who received a stem-cell dose of \< 3.9 × 10^6^ cells/kg in FH-CEM and SZ-Bu/Mel cohorts. This finding was similar to that reported by Morgenstern et al.^[@B35]^ Desai et al^[@B26]^ compared the time to neutrophil and platelet engraftment between Bu/Mel and CEM for the treatment of patients with HRNB who received the same dose of infused CD34-positive cells per kilogram and found no significant difference in the time to neutrophil and platelet engraftments between both cohorts.

Nephrotoxicity was significantly more frequent after conditioning with FH-CEM compared with SZ-Bu/Mel. Several studies have reported similar results.^[@B12]-[@B29]^ This is likely correlated with the use of high-dose carboplatin. Carboplatin is a platinum derivative that is less toxic than cisplatin but still associated with a decrease in the glomerular filtration rate and hypomagnesaemia.^[@B36]^ There were two patients after SZ-Bu/Mel conditioning who required renal dialysis as a result of hepato-renal syndrome secondary to severe SOS.

Despite the differences in economic status between Egypt and the United States, we found no significant difference in the frequency of blood stream infections between the two cohorts. This may suggest that the overall quality of supportive care provided to these vulnerable, high-risk patients in a lower middle-income country was equivalent to that in a high-income country.

There was a trend toward a higher, but insignificant, percentage of Gram-negative organisms in the SZ-Bu/Mel cohort compared with the FH-CEM cohort. This is in agreement with other reports that have noted the re-emergence of infections with Gram-negative organisms in Egypt.^[@B37]^

Overall, resource utilization was greater in the FH-CEM cohort than in the SZ-Bu/Mel cohort, as evidenced by a significantly higher number of days with fever, antibiotic use, and number of packed RBC and platelet transfusions administered. Thus, SZ-Bu/Mel is more suitable to be used as HDC-SCR for the treatment of HRNB in lower middle-income Egypt.

Our study is limited by its retrospective design that included two different centers with different practice guidelines and resources; however, these data demonstrate that, compared with a well-established program, such as that in the United States, the utilization of a highly technical intensive therapy, such as BMT, can be safely undertaken in a developing country. It also demonstrates the unique challenges that exist for a country with endemic hepatitis that lead to significantly higher risks of potentially fatal hepatic toxicity.

In conclusion, use of HDC-SCR is feasible in the context of a resource-limited country. Bu/Mel is preferred in Egypt because of fewer infections, lower resource utilization, and less nephrotoxicity, although its contribution to hepatic complications is still a major concern and requires consideration of earlier supportive and/or prophylactic interventions.

Supported by a scholarship from the Ministry of High Education, Egypt (to M.M.E.).

AUTHOR CONTRIBUTIONS {#s21}
====================

**Conception and design:** Julie R. Park, Khaled F. Riad, Heba A. Sayed, Navin Pinto, K. Scott Baker, Alaa El-Haddad, Mahmoud M. Elzembely

**Provision of study materials or patients:** K. Scott Baker

**Collection and assembly of data:** Mahmoud M. Elzembely, Alaa El-Haddad

**Data analysis and interpretation:** Mahmoud M. Elzembely, Julie R. Park, Navin Pinto, Paul A. Carpenter

**Manuscript writing:** All authors

**Final approval of manuscript:** All authors

**Accountable for all aspects of the work:** All authors

AUTHORS\' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST {#s22}
========================================================

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO\'s conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [ascopubs.org/jco/site/ifc](http://www.ascopubs.org/jco/site/ifc).

Mahmoud M. Mohammed {#s23}
-------------------

No relationship to disclose

Julie R. Park {#s24}
-------------

**Honoraria:** Bristol-Myers Squibb

**Travel, Accommodations, Expenses:** Roche

Khaled F. Riad {#s25}
--------------

No relationship to disclose

Heba A. Sayed {#s26}
-------------

No relationship to disclose

Navin Pinto {#s27}
-----------

No relationship to disclose

Paul A. Carpenter {#s28}
-----------------

**Consulting or Advisory Role:** Mallinckrodt, Incyte

**Research Funding:** Mesoblast, Mallinckrodt

**Travel, Accommodations, Expenses:** Pharmacyclics

K. Scott Baker {#s29}
--------------

No relationship to disclose

Alaa El-Haddad {#s30}
--------------

No relationship to disclose
